Enanta Pharmaceuticals (ENTA) Cash from Operations (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Cash from Operations of 7156000.0 for Q1 2026, up 38.83% on a QoQ basis from 11699000.0 in Q4 2025, and up 46.95% year-over-year from 4869834.91 in Q1 2025.
Enanta Pharmaceuticals (ENTA) Cash from Operations (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Cash from Operations history runs 15 years deep, the most recent figure standing at 7156000.0 for Q1 2026.
- Quarterly Cash from Operations rose 46.95% year-over-year to 7156000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7838000.0 (up 85.87% YoY) and the FY2025 annual result came in at 19272000.0, up 75.53% from the prior year.
- Cash from Operations was 7156000.0 for Q1 2026 at Enanta Pharmaceuticals, up from 11699000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 17506000.0 in Q2 2025 and bottomed at 35641000.0 in Q4 2022.
- A 5-year average of 17150352.94 and a median of 15534000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 476.0% — and 2025, when it surged 218.48%.
- Enanta Pharmaceuticals' Cash from Operations stood at 35641000.0 in 2022, then advanced by 29.89% to 24988000.0 in 2023, then soared by 32.76% to 16801000.0 in 2024, then surged by 30.37% to 11699000.0 in 2025, then jumped by 38.83% to 7156000.0 in 2026.
- Business Quant data shows ENTA's Cash from Operations at 7156000.0 in Q1 2026, 11699000.0 in Q4 2025, and 6489000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -7.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.16 Mn |
| Mar 31, 2026 | -7.16 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Sep 30, 2025 | -6.49 Mn |
| Sep 30, 2025 | -6.49 Mn |
| Jun 30, 2025 | 17.51 Mn |
| Jun 30, 2025 | 17.51 Mn |
| Mar 31, 2025 | -13.49 Mn |
| Mar 31, 2025 | -13.49 Mn |
| Dec 31, 2024 | -16.80 Mn |
| Dec 31, 2024 | -16.80 Mn |
| Sep 30, 2024 | -10.40 Mn |
| Sep 30, 2024 | -10.40 Mn |
| Jun 30, 2024 | -14.78 Mn |
| Jun 30, 2024 | -14.78 Mn |
| Mar 31, 2024 | -28.60 Mn |
| Mar 31, 2024 | -28.60 Mn |
| Dec 31, 2023 | -24.99 Mn |
| Dec 31, 2023 | -24.99 Mn |